Frost & Sullivan Manufacturing

JANUARY 29, 2024

billion CNY in 2027. billion CNY in 2027. billion CNY in 2027. billion by 2027. billion by 2027. Trautec, with large-scale, eco-friendly production of collagen types I, II, III, and XVII SRHC, has expanded globally, securing partnerships with 30+ cosmetic and pharmaceutical leaders. in 2017 to 18.5%

Function 52

Function Pharmaceutical Sourcing 52

i4.0 today

SEPTEMBER 5, 2024

BTX compounds are essential building blocks for a wide array of high-value chemicals and materials, including plastics, paints, sealants, coatings, and pharmaceuticals. billion by 2027. Aromatic chemicals like BTX are key building blocks, accounting for 40% of petrochemical production by volume.

Pharmaceutical 52

Pharmaceutical Sourcing Industry 4.0 Industry 4.0 52

E&T

JULY 7, 2023

These cells are like ‘keys on a piano’ and range from low to high frequency, explains Dr Robert Gay, director of pharmaceutical approaches at Cochlear, a Sydney-based manufacturer of the device. Three-and-a-half-thousand acoustic hair cells in the inner and outer cochlea convert vibration of sound into an electrical signal into the brain.

Pharmaceutical 111

Pharmaceutical Bottleneck Fit Electronics 111

Fabricating & Metal Work

OCTOBER 2, 2023

With the facility, ABB will expand production capacity by 50 percent and strengthen its capabilities to supply the European market, which is expected to grow at seven percent CAGR through 2027 1. Source: Interact Analysis www.abb.com go.abb/robotics Subscribe to learn the latest in manufacturing.

Robotics 52

Robotics Robotics Automation Pharmaceutical 52

Foley

JULY 11, 2023

Companies that may be concerned about the viability or performance of a supplier should consider seeking licenses or other rights that would enable to obtain vital components from another source if the supplier does not meet its obligations. Healthcare and Pharmaceuticals. This directive is not limited to supply contracts alone.

Manufacturing 40

Manufacturing Compliance Supply Chain Form 40

Canadian Manufacturing

APRIL 17, 2024

This investment is in addition to a $2-billion CAD joint investment with governments at all levels at our Toronto Campus to build two new state-of-the-art vaccine manufacturing facilities by 2027.”

Sourcing 52

Sourcing Manufacturing Pharmaceutical 52